New forces on the anti-thrombosis track! Nanjing is sunny 4 varieties through the consistent evaluation.

If you take into account the four categories of registered and approved since July 2019, hydrogen sulfate clopidogrel tablets, apixaban tablets, tigrillo tablets, and the November 2019 approved listing of agaculban injections, Nanjing Zhengtianqing quickly became one of the most abundant pharmaceutical varieties on the domestic antithrombosis drug circuit layout.
From the development trend of the domestic generic drug market, a large variety of market share will be concentrated in the hands of a limited number of manufacturers, and around a disease area of "grouping" of the overall variety layout is more able to hedge the risk to play a synergistic advantage.
For example, the third batch of national volume procurement will land in late August, Apixaban film and Tigrello film these two varieties of the current competitive situation is 7 into 5 and 8 into 6, from the market increment and track varieties synergy point of view, Nanjing Zhengtianqing for these two varieties should be ambitious.
, the price reduction of the two incremental varieties in addition to itself can be exchanged for a certain market, but also can co-promote the sale of non-collected varieties in the corresponding market.
oral anti-thrombosis drugs and collection status anti-thrombosis drugs, which have been evaluated consistently, have a variety of clinical use scenarios, the applicable population base is large, and the demand for medication is stable.
From the mechanism of action, oral thrombosis drugs mainly include anti-plateroid drugs, such as clopidogrel, tigrillo, and anticoagulant drugs, such as devasaban, apixaban, dabiga esters.
According to the medical Rubik's Cube IPM data, the 2020 sales data of five sample hospitals of hydrochlorochloride tablets, devasabin tablets, tigrillo tablets, dabiga group ester capsules, apixaban tablets, reached 11 billion yuan, which is a very considerable market.
anti-thrombosis drugs for Nanjing Zhengtianqing is a complete incremental market, as long as the winning bid to enter the market is a success.
Oral antithrombosis drug sample hospital sales revenue (billion yuan) So far, Nanjing Zhengda Tianqing has 12 varieties in the new 4 categories of registration or supplementary applications through the consistent evaluation, but also through the consistent evaluation of the number of varieties TOP15 pharmaceutical enterprises.
Through the consistent evaluation of varieties TOP10 enterprises Nanjing Zhengda Tianqing through the consistency evaluation of varieties from the specific strategy of consistency evaluation, Nanjing Zhengtianqing priority layout and through consistency evaluation of the varieties are mainly concentrated in the cardiovascular field of oral preparations, in addition to the above four anti-thrombosis drugs, but also includes the mainstream varieties of antihyptophan, blood lipids, reshuvastatin calcium tablets, erbesatan hydrochloride tablets, omstatin tablets.
Nanjing Zhengda Tianqing other varieties that are applying for consistency evaluation are some of the injection varieties that will be submitted from 2019 onwards, including boron-zomi for injections, gisithamin for injection hydrochloric acid, iodized kesal alcohol injections, etc.
.